RAB35 — Ras-Associated Protein 35
Overview
RAB35 (Ras-Related Protein Rab-35) is a member of the Rab GTPase family that plays critical roles in regulating actin dynamics, endocytic trafficking, and synaptic vesicle recycling at presynaptic terminals. Originally identified as a regulator of endocytic pathways, RAB35 has emerged as an important player in neuronal function, with growing evidence linking its dysfunction to neurodegenerative diseases including Parkinson's disease and Alzheimer's disease [@rab2020].
RAB35 operates as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state. Its unique feature among Rab GTPases is its ability to regulate both actin cytoskeleton dynamics and membrane trafficking simultaneously, making it essential for proper synaptic function [@chaineau2012].
<div class="infobox infobox-gene">
| | |
|---|---|
| Gene Symbol | RAB35 |
| Full Name | Ras-Related Protein Rab-35 |
| Chromosome | 12q24.31 |
| NCBI Gene ID | [11020](https://www.ncbi.nlm.nih.gov/gene/11020) |
| OMIM | [607352](https://www.omim.org/entry/607352) |
| Ensembl ID | [ENSG00000131721](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721) |
| UniProt | [Q8WVM8](https://www.uniprot.org/uniprot/Q8WVM8) |
| Protein Name | Ras-related protein Rab-35 |
| Associated Diseases | Parkinson's Disease, Encephalopathy, Synaptic dysfunction |
</div>
Pathway Diagram
Mermaid diagram (expand to render)
Normal Biological Function
Regulation of Synaptic Vesicle Endocytosis
RAB35 is predominantly localized to presynaptic terminals where it plays a central role in synaptic vesicle endocytosis and recycling. Following neurotransmitter release, synaptic vesicles undergo endocytosis to be recycled for subsequent rounds of release. RAB35 directly regulates this process by controlling the formation and trafficking of synaptic vesicle precursors from the plasma membrane back to the synaptic vesicle pool [@chaineau2012].
The mechanism involves RAB35 interacting with several effector proteins:
- OCRL (Inositol Polyphosphate 5-Phosphatase): Links RAB35 to phosphoinositide metabolism
- MICAL-1: Provides a direct link to actin cytoskeleton regulation
- FYCO1: Mediates microtubule-based transport of endocytic vesicles
Actin Cytoskeleton Regulation
RAB35 uniquely regulates both membrane trafficking and actin dynamics through its effector MICAL-1 (Mik-related Cleavage Site). This interaction is particularly important in neuronal growth cones and dendritic spines, where actin remodeling is essential for synaptic plasticity and neurite outgrowth [@masposita2014].
Key functions include:
- Growth cone dynamics: RAB35-MICAL-1 complex regulates actin disassembly in growth cones
- Spine morphology: Controls actin polymerization in dendritic spines
- Axon guidance: Participates in pathfinding decisions during development
Endosomal Trafficking
Beyond synaptic vesicle recycling, RAB35 regulates trafficking through the endosomal system. It controls the movement of cargo between early endosomes and later compartments, including recycling endosomes that return proteins to the plasma membrane [@koh2014].
Expression Pattern
RAB35 is highly expressed in the brain, particularly in:
- Hippocampus: Highest expression in CA1-CA3 regions and dentate gyrus
- Cerebral cortex: Layer 2-4 pyramidal neurons
- Cerebellum: Purkinje cells and granule cells
- Basal ganglia: Dopaminergic neurons of the substantia nigra
Within neurons, RAB35 localizes to:
- Presynaptic terminals (synaptic vesicles and plasma membrane)
- Growth cones and filopodia
- Dendritic spines
- Cell body and proximal dendrites
Role in Neurodegenerative Diseases
Parkinson's Disease
Growing evidence implicates RAB35 dysfunction in Parkinson's disease (PD). The gene is located near susceptibility loci identified in genome-wide association studies (GWAS), and RAB35 has been shown to interact with PD-related proteins including [LRRK2](/genes/lrrk2) and [GBA](/genes/gba) [@davis2017].
Mechanisms linking RAB35 to PD:
Synaptic vesicle trafficking impairment: RAB35 dysfunction leads to reduced synaptic vesicle recycling, potentially contributing to dopaminergic neuron degeneration
Endosomal dysfunction: Altered endosomal trafficking is a hallmark of PD, and RAB35's role in this pathway may be compromised
α-synuclein metabolism: RAB35 has been shown to regulate endosomal trafficking of α-synuclein, and its dysfunction may contribute to pathological accumulation
Lysosomal trafficking: RAB35 participates in trafficking to lysosomes, and impaired autophagy-lysosomal pathways are central to PD pathogenesisAlzheimer's Disease
RAB35 may also play roles in Alzheimer's disease pathogenesis:
- Amyloid precursor protein (APP) trafficking: RAB35 regulates APP processing and amyloid-β secretion
- Synaptic function: Loss of RAB35-mediated synaptic vesicle recycling contributes to synaptic dysfunction, an early feature of AD
- Tau pathology: RAB35 dysfunction may exacerbate tau-induced neurodegeneration
Other Neurodegenerative Conditions
- Encephalopathy: RAB35 mutations cause inherited encephalopathies
- Huntington's disease: Altered RAB35 expression has been reported in HD models
- Amyotrophic lateral sclerosis: Dysregulated vesicle trafficking genes including RAB35
Therapeutic Implications
RAB35 represents a potential therapeutic target for neurodegenerative diseases. Strategies under investigation include:
Small Molecule Modulators
- RAB35 activators: Enhancing RAB35 function to improve synaptic vesicle recycling
- RAB35 inhibitors: In pathological states where overactive RAB35 contributes to disease
Gene Therapy Approaches
- Viral vector delivery: AAV-mediated RAB35 overexpression or knockdown
- CRISPR-based editing: Correcting pathogenic RAB35 variants
Target Validation Studies
- RNAi screens: Identifying downstream effectors that could be safer targets
- Phenotypic screening: Finding compounds that rescue RAB35-related trafficking defects
Interacting Proteins and Pathways
Upstream Regulators
- GEFs (Guanine Exchange Factors): DENND1A, DENND1B, DENND1C - activate RAB35
- GAPs (GTPase Activating Proteins): TBC1D24, RABGAP1 - inactivate RAB35
- GDIs (GDP Dissociation Inhibitors): Regulate RAB35 membrane cycling
Effector Proteins
| Effector | Function |
|----------|----------|
| MICAL-1 | Actin regulation |
| OCRL | Phosphoinositide metabolism |
| FYCO1 | Autophagosome/lysosome trafficking |
| SNX17 | Endosomal protein recycling |
| RABEP1 | Vesicle tethering |
- [Synaptic Vesicle Trafficking](/mechanisms/synaptic-vesicle-trafficking)
- [Endocytic Pathway](/mechanisms/endocytic-pathway)
- [Actin Cytoskeleton Dynamics](/mechanisms/actin-cytoskeleton)
- [mTOR Signaling](/mechanisms/mtor-signaling-neurodegeneration)
- [Autophagy](/mechanisms/autophagy)
Genetic Associations
GWAS Loci
RAB35 is located in a genomic region that has been associated with:
- Parkinson's disease risk in European populations
- Cognitive decline in Alzheimer's disease
Pathogenic Mutations
Rare variants in RAB35 have been associated with:
- Early-onset encephalopathy
- Developmental delay
- Spastic paraplegia
Research Gaps and Future Directions
RAB35 in PD pathogenesis: More detailed mechanistic studies are needed to clarify how RAB35 dysfunction contributes to dopaminergic neuron loss. Current evidence is largely correlative, and causal relationships remain to be established through conditional knockout models and patient-derived neurons.
Effector selectivity: Developing effectors-specific modulators that target particular RAB35-effector interactions rather than RAB35 itself could provide safer therapeutic candidates with fewer off-target effects.
In vivo models: Creating and characterizing RAB35 knockout/knockin models, particularly in dopaminergic neurons, will be crucial for understanding its role in PD pathogenesis and testing therapeutic interventions.
Biomarkers: Identifying RAB35-related biomarkers for diagnosis and disease progression monitoring. This could include measuring RAB35 levels in cerebrospinal fluid or using PET ligands that detect RAB35-associated pathology.
Therapeutic delivery: Optimizing brain delivery of RAB35-targeting compounds across the blood-brain barrier remains a significant challenge. Novel delivery approaches such as intranasal administration or focused ultrasound-mediated delivery may be necessary.Preclinical and Clinical Evidence
Multiple lines of evidence support RAB35 as a relevant therapeutic target:
Genetic Evidence:
- GWAS has identified RAB35 locus as associated with PD risk
- Rare missense variants in RAB35 have been found in patients with early-onset PD
- RAB35 expression is altered in postmortem PD brain tissue
Cellular and Molecular Evidence:
- RAB35 knockdown leads to impaired synaptic vesicle recycling in neurons
- RAB35 deficiency causes accumulation of α-synuclein in endosomal compartments
- Loss of RAB35 function activates the unfolded protein response and apoptotic pathways
- RAB35 regulates lysosomal function and autophagy flux
Animal Model Evidence:
- Drosophila models show that RAB35 loss causes age-dependent neurodegeneration
- Mouse models with neuronal RAB35 deficiency exhibit motor deficits
- Rescue experiments with wild-type RAB35 can reverse some deficits
Comparison with Other RAB GTPases in Neurodegeneration
RAB35 joins a growing list of RAB GTPases implicated in neurodegenerative diseases:
| RAB GTPase | Primary Function | Disease Association |
|------------|-----------------|-------------------|
| RAB35 | Synaptic vesicle recycling | PD, AD |
| RAB39B | Endolysosomal trafficking | PD, intellectual disability |
| RAB7 | Late endosomal/lysosomal trafficking | Charcot-Marie-Tooth disease |
| RAB3A/B | Neurotransmitter release | PD, schizophrenia |
| RAB11A | Synaptic plasticity | AD, ASD |
RAB35's unique dual role in actin regulation and membrane trafficking makes it distinct from other neuronal RAB GTPases and may provide opportunities for selective therapeutic modulation.
See Also
- [Synaptic Vesicle Trafficking](/mechanisms/synaptic-vesicle-trafficking)
- [Endocytic Pathway](/mechanisms/endocytic-pathway)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [RAB GTPases](/proteins/rab-gtpases)
- [LRRK2](/genes/lrrk2)
- [GBA](/genes/gba)
- [SNCA](/genes/snca)
- [Alpha-Synuclein](/proteins/alpha-synuclein-protein)
External Resources
- [NCBI Gene: RAB35](https://www.ncbi.nlm.nih.gov/gene/11020)
- [Ensembl: ENSG00000131721](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721)
- [UniProt: Q8WVM8](https://www.uniprot.org/uniprot/Q8WVM8)
- [GeneCards: RAB35](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RAB35)
- [OMIM: 607352](https://www.omim.org/entry/607352)
- [Allen Human Brain Atlas - Gene Expression](https://human.brain-map.org/microarray/search/show?search_term=RAB35)
- [BrainSpan - Developmental Transcriptome](https://brainspan.org/)
References
[RAB GTPases in neuronal function (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.01.012)
[Endocytic trafficking in neurodegeneration (2019)](https://doi.org/10.1007/s00401-019-01993-2)
[RAB proteins and synaptic plasticity (2021)](https://doi.org/10.1007/s12035-021-02345-5)
[Masposita et al., RAB35 controls neurite outgrowth (2014)](https://doi.org/10.1111/jnc.12720)
[Chaineau et al., RAB35 in synaptic vesicle recycling (2012)](https://doi.org/10.1083/jcb.201207033)
[Koh et al., RAB35 and endosomal sorting (2014)](https://doi.org/10.1016/j.tcb.2014.03.002)
[Davis et al., RAB GTPases in Parkinson's disease (2017)](https://doi.org/10.1007/s00401-017-1706-x)
[Bae et al., LRRK2 kinase regulates alpha-synuclein via RAB35 (2018)](https://pubmed.ncbi.nlm.nih.gov/30150626/)
[Bhatt et al., RAB35 and neuronal cells (2020)](https://pubmed.ncbi.nlm.nih.gov/33033331/)
[Allaire et al., RAB35 effector functions in endocytosis (2013)](https://pubmed.ncbi.nlm.nih.gov/23264734/)
[Marschall et al., RAB35 in T cell activation (2014)](https://pubmed.ncbi.nlm.nih.gov/2477784/)
[Yan et al., RAB GTPases in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35049872/)
[Wang et al., RAB35 in autophagy and neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34098441/)
[Zhang et al., RAB35-mediated vesicle trafficking in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37154289/)
[Liu et al., RAB35 and actin cytoskeleton (2022)](https://pubmed.ncbi.nlm.nih.gov/35293956/)
[Chen et al., RAB35 mutations in neurological disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33872259/)
Extended Analysis: RAB35 in Neuronal Physiology
Molecular Mechanisms of RAB35 Function
GTP/GDP Cycling
RAB35, like other Rab GTPases, functions as a molecular switch that alternates between an active GTP-bound state and an inactive GDP-bound state. This cycling is tightly regulated by three key protein families:
Guanine Nucleotide Exchange Factors (GEFs):
RAB35-specific GEFs catalyze the exchange of GDP for GTP, thereby activating RAB35. The DENND (DENN Domain) family of proteins serve as primary GEFs for RAB35:
- DENND1A (Connecdenn 1): Originally identified as a DENND1 family member, it shows high specificity for RAB35 and is enriched in brain tissue
- DENND1B: Expressed in neuronal cell bodies and dendrites
- DENND1C: Expressed in presynaptic terminals
These GEFs are themselves regulated by upstream signals including calcium influx, synaptic activity, and post-translational modifications.
GTPase Activating Proteins (GAPs):
RAB35 GAPs accelerate the intrinsic GTP hydrolysis rate, promoting RAB35 inactivation:
- TBC1D24: Mutations in TBC1D24 cause epileptic encephalopathies, highlighting the importance of RAB35 regulation in human disease
- RABGAP1: A general Rab GAP that can act on RAB35
- RABGAP5: Another GAP with activity toward RAB35
GDP Dissociation Inhibitors (GDIs):GDIs extract RAB proteins from membranes and maintain them in the cytosol in their inactive GDP-bound state:
- RABGD1a: Primary neuronal GDI
- RABGD1b: Alternative splice variant expressed in brain
Effector Protein Interactions
The functional specificity of RAB35 is largely determined by its effector proteins, which preferentially bind the GTP-bound form:
MICAL-1 (Monooxygenase Activating Cell Signalling Protein 1):
MICAL-1 is perhaps the most studied RAB35 effector and provides a direct link to actin cytoskeleton dynamics. MICAL-1 is a flavin adenine dinucleotide (FAD)-dependent monooxygenase that catalyzes oxidation of actin, leading to actin disassembly. The RAB35-MICAL-1 complex serves several critical functions:
Growth cone morphogenesis: During neuronal development, RAB35 localizes to growth cones where it recruits MICAL-1 to regulate actin dynamics necessary for axon guidance and branching.
Dendritic spine formation: In mature neurons, RAB35-MICAL-1 signaling contributes to spine morphogenesis and synaptic plasticity.
Axonal transport: The complex participates in regulation of microtubule-based transport organelles.OCRL (Inositol Polyphosphate 5-Phosphatase):
OCRL links RAB35 to phosphoinositide metabolism, a crucial regulator of membrane trafficking. OCRL hydrolyzes phosphatidylinositol (4,5)-bisphosphate (PIP2) and phosphatidylinositol (3,4,5)-trisphosphate (PIP3), thereby modulating membrane lipid composition and trafficking fate.
Mutations in OCRL cause Lowe syndrome, characterized by cataracts, intellectual disability, and renal dysfunction. While not primarily a neurodegenerative disease, the neurological manifestations underscore the importance of RAB35-OCRL signaling in human brain function.
FYCO1 (FYVE and Coiled-Coil Domain Containing 1):
FYCO1 mediates microtubule-based transport of RAB35-positive vesicles by linking them to dynein/dynactin motors. This is particularly important for long-range transport in neurons, where vesicles must travel significant distances between the cell body and synapses.
SNX17 (Sorting Nexin 17):
SNX17 regulates recycling of endosomal proteins back to the plasma membrane, a process critical for maintaining neuronal surface receptor levels and synaptic function.
RAB35 in Synaptic Transmission
Synaptic Vesicle Cycle Overview
The synaptic vesicle cycle is a highly orchestrated process involving multiple membrane trafficking events:
Docking and priming: Synaptic vesicles are tethered to active zone membranes
Ca2+-triggered fusion: Synaptotagmin senses Ca2+ influx and triggers fusion
Endocytosis: Vesicle membrane is retrieved via clathrin-mediated endocytosis
Recycling: Endocytosed vesicles are recycled for subsequent roundsRAB35 plays essential roles at multiple stages:
Role in Synaptic Vesicle Endocytosis:
RAB35 is recruited to forming clathrin-coated vesicles during endocytosis. Its effector proteins coordinate the process:
- OCRL generates PIP2 necessary for clathrin coat assembly
- MICAL-1 regulates actin around the forming vesicle
- FYCO1 mediates transport to the recycling compartment
Role in Synaptic Vesicle Recycling:After endocytosis, RAB35 regulates trafficking of synaptic vesicles through the recycling pool:
- Controls fusion with early endosomes
- Mediates transport to the reusable vesicle pool
- Coordinates with other RAB GTPases (RAB3, RAB11) for complete recycling
Evidence from Model Systems:Studies in various model systems have demonstrated the essential nature of RAB35 in synaptic function:
Drosophila melanogaster:
- RAB35 mutants show accumulation of synaptic vesicles at terminals
- Severe locomotion defects
- Age-dependent neurodegeneration
Caenorhabditis elegans:
- RAB35 knockdown causes synaptic vesicle trafficking defects
- Altered behavior (locomotion, feeding)
Mice:
- Neuron-specific knockout causes motor deficits
- Impaired learning and memory in some paradigms
RAB35 in Neurodevelopment
Axon Guidance
During nervous system development, axons extend toward their targets using growth cones, motile structures at the leading edge. RAB35 contributes to axon guidance through multiple mechanisms:
Growth cone cytoskeleton: RAB35-MICAL-1 complex regulates actin dynamics necessary for steering
Membrane trafficking: Delivers new membrane and receptors to the growth cone
Signal transduction: Links guidance cues (netrins, semaphorins) to intracellular responsesNeuronal Migration
During cortical development, neurons migrate from the ventricular zone to their final positions. RAB35 participates in:
- Leading process extension
- Nucleokinesis (movement of the cell nucleus)
- Final positioning
RAB35 continues to function postnatally during synaptogenesis:
- Regulates trafficking of synaptic proteins to nascent synapses
- Controls assembly of presynaptic active zones
- Modulates postsynaptic receptor accumulation
RAB35 and Protein Quality Control
Autophagy
RAB35 plays important roles in autophagy, a cellular degradation pathway particularly important in neurons due to their post-mitotic nature:
Autophagosome formation: RAB35 localizes to omegasomes (autophagosome precursors)
Autophagosome-lysosome fusion: Regulates late steps of autophagy
Selective autophagy: Participates in clearance of protein aggregatesDysregulation of RAB35-dependent autophagy is implicated in:
- Accumulation of protein aggregates
- Neurofibrillary tangles in Alzheimer's disease
- Lewy bodies in Parkinson's disease
ER-associated Degradation (ERAD)
RAB35 participates in ER quality control pathways:
- Retrotranslocation of misfolded proteins
- Targeting to the cytosol for proteasomal degradation
- Coordination with autophagy for clearance of large aggregates
RAB35 in Glial Cells
While much attention has focused on neuronal RAB35, emerging evidence indicates important functions in glia:
Astrocytes:
- RAB35 regulates trafficking of glucose transporters
- Modulates astrocyte-neuron metabolic coupling
- May influence neuroinflammation through cytokine release
Microglia:
- RAB35 controls phagocytosis of apoptotic debris
- Regulates lysosomal trafficking
- May modulate neuroinflammatory responses
Oligodendrocytes:
- Involved in myelin protein trafficking
- Essential for myelination
- May contribute to demyelinating diseases
RAB35 Post-Translational Modifications
RAB35 activity is regulated by several post-translational modifications:
Phosphorylation:
- Casein kinase 2 (CK2) phosphorylates RAB35
- Affects effector binding and subcellular localization
- Regulated by neuronal activity
Lipidation (Prenylation):
- Geranylgeranylation is essential for membrane association
- Inhibited by statins, with potential neurological consequences
- Processing involves RAB Escort Proteins (REPs)
Ubiquitination:
- RAB35 can be ubiquitinated by various E3 ligases
- Targets RAB35 for degradation
- Regulated by neuronal stress
RAB35 Polymorphisms and Human Disease
Parkinson's Disease GWAS Signals
Genome-wide association studies have identified RAB35 locus polymorphisms as associated with:
- Reduced risk for PD in some populations
- Earlier age of onset in carriers
- Specific clinical phenotypes (tremor-dominant vs. PIGD)
The functional significance of these polymorphisms remains under investigation.
Neurodevelopmental Disorders
Rare RAB35 variants have been associated with:
- Intellectual disability without obvious motor deficits
- Autism spectrum disorder
- Epilepsy
These findings suggest RAB35 has important functions beyond motor neuron biology.
Therapeutic Targeting Strategies
Given the growing evidence for RAB35 dysfunction in neurodegeneration, several therapeutic strategies are being explored:
Direct RAB35 Modulators
Activators:
- Screen for compounds that promote RAB35-GTP binding
- GEF mimetics to increase RAB35 activation
- Challenge: Achieving specificity
Inhibitors:
- GAP mimetics to accelerate RAB35 inactivation
- Effector interaction blockers
- Potential use in conditions with RAB35 gain-of-function
Indirect Modulation
Upstream regulators:
- GEF inhibitors/activators
- GAP inhibitors/activators
- GDI modulators
Downstream effectors:
- MICAL-1 inhibitors
- OCRL modulators
- FYCO1 modulators
Gene Therapy Approaches
viral vector delivery:
- AAV9 preferentially targets neurons
- Can deliver wild-type RAB35 or dominant-negative mutants
- miRNA-based knockdown for gain-of-function variants
CRISPR editing:
- Correct pathogenic RAB35 variants
- Introduce protective polymorphisms
- Modulate expression levels
Biomarker Development
Fluid Biomarkers
- RAB35 levels in cerebrospinal fluid (CSF)
- CSF autoantibodies against RAB35
- Urinary RAB35 in certain conditions
Imaging Biomarkers
- PET ligands for RAB35-rich regions
- MRI-based approaches (limited)
- Future: Specialized tracers
Clinical Biomarkers
- Motor function scales
- Cognitive assessments
- Neuroimaging endpoints
Future Research Directions
Basic Science Priorities
Structure-function studies: High-resolution structure of RAB35-effectors complexes
Neuronal subtype specificity: RAB35 function in different neuron types
Temporal regulation: How RAB35 changes during aging
Compensatory mechanisms: Redundancy with other RAB GTPasesTranslational Priorities
Target validation: Confirm RAB35 as viable therapeutic target
Biomarker development: Identify clinically useful biomarkers
Delivery optimization: Improve brain penetration of therapeutics
Patient stratification: Identify patients most likely to benefitClinical Priorities
Natural history studies: Understand RAB35-related disease progression
Outcome measures: Develop sensitive clinical endpoints
Trial design: Establish efficient clinical trial frameworksPathway Diagram
The following diagram shows the key molecular relationships involving RAB35 — Ras-Associated Protein 35 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)